AstraZeneca Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St

February 22, 2025

AstraZeneca (LON:AZN) Full Year 2024 Results

Key Financial Results

Revenue: US$54.1b (up 18% from FY 2023).
Net income: US$7.04b (up 18% from FY 2023).
Profit margin: 13% (in line with FY 2023).
EPS: US$4.54 (up from US$3.84 in FY 2023).

AZN Products In Clinical Trials

Phase I: 39.
Phase II: 32.
Phase III: 38.

AZN Post-Clinical Trial Products

Pre-registration: 19.
Approved (during full year): 22.

revenue-and-expenses-breakdown — LSE:AZN Revenue and Expenses Breakdown February 22nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

AstraZeneca Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates by 16%.

The primary driver behind last 12 months revenue was the United States segment contributing a total revenue of US$21.8b (40% of total revenue). The largest operating expense was General & Administrative costs, amounting to US$18.9b (51% of total expenses). Explore how AZN's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom.

Performance of the British Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for AstraZeneca that you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.